SCHEMBL10101753

SCHEMBL10101753

C/C(=N\OCc1ccc(C)cc1)c1cc(O)c(C)cc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
S1PR1 P21453 7/20 0.40
MAPT P10636 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
CA12 O43570 1/20 0.39
LMNA P02545 2/20 0.38
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
ESR2 Q92731 1/20 0.35
MAOB P27338 1/20 0.35
PPARG P37231 2/20 0.35
PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10101769 0.94 S1PR1 (0.42) MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL10101765 0.88 CA12 (0.44) L3MBTL1SMN1; SMN2S1PR1MAPTPOLB
SCHEMBL10101774 0.88 BACE1 (0.40) MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL10101760 0.88 L3MBTL1 (0.42) L3MBTL1NPC1RAB9AS1PR1MAPT
SCHEMBL10101757 0.87 S1PR1 (0.41) MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL10102114 0.86 MAPT (0.45) MAPK1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL10101773 0.85 S1PR1 (0.43) L3MBTL1S1PR1MAPTPOLBGAA
SCHEMBL10102149 0.84 SMN1; SMN2 (0.40) MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL10101767 0.84 S1PR1 (0.40) MAPK1L3MBTL1S1PR1MAPTPOLB
SCHEMBL10101752 0.83 POLB (0.41) MAPK1L3MBTL1SMN1; SMN2S1PR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536157-B2 Non-steroidal compounds THE UNIVERSITY OF MELBOURNE (AU) 2013-09-17 US disclosed
US-20120046255-A1 NON-STEROIDAL COMPOUNDS THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046255-A1 NON-STEROIDAL COMPOUNDS PTGES2, PTGES, PTGES3 MAPK1 3818/4885L3MBTL1 4843/4885NPC1 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.